Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ALTO-207

Other · developed by Alto Neuroscience

Phase 2 Most advanced trial
ANRO Developer
1 Registered trials

What is ALTO-207?

ALTO-207 is an investigational drug studied in Treatment-resistant Depression (TRD).

At a glance

Drug type
Other
Therapy area
Psychiatry
Developer
Alto Neuroscience (ANRO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07553637 Phase 2 Treatment-resistant Depression (TRD) Recruiting ANRO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Treatment-resistant Depression (TRD)

More from Alto Neuroscience

ALTO-100 Phase 2 ALTO-101 Phase 2 ALTO-203 Phase 2 ALTO-300 Phase 2

Follow ANRO, the company behind ALTO-207

See ANRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANRO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.